Neuropharm Group plc
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neuropharm Group plc
Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
China's CARsgen Raises $400m In Third-Largest Biotech IPO This Year
Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.
Asia Deal Watch: Kyongbo To Supply Ceftobiprole API For Basilea
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice